Previous Close | 4.7700 |
Open | 4.7900 |
Bid | 4.6500 x 800 |
Ask | 4.6700 x 2200 |
Day's Range | 4.5800 - 4.7900 |
52 Week Range | 0.2700 - 34.0000 |
Volume | |
Avg. Volume | 168,798 |
Market Cap | 27.669M |
Beta (5Y Monthly) | 1.05 |
PE Ratio (TTM) | 0.11 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.